These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 26875002)

  • 1. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
    Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
    J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
    Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
    Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
    Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
    Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
    Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
    Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase II Randomized Controlled Study.
    Brandt JD; Sall K; DuBiner H; Benza R; Alster Y; Walker G; Semba CP;
    Ophthalmology; 2016 Aug; 123(8):1685-1694. PubMed ID: 27157843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
    Fingeret M; Gaddie IB; Bloomenstein M
    Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle Glaucoma or Ocular Hypertension.
    Sarkisian SR; Ang RE; Lee AM; Berdahl JP; Heersink SB; Burden JH; Doan LV; Stephens KG; Kothe AC; Usner DW; Katz LJ; Navratil T;
    Ophthalmology; 2024 Sep; 131(9):1021-1032. PubMed ID: 38423216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
    Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
    Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
    Kawase K; Vittitow JL; Weinreb RN; Araie M;
    Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension.
    Diestelhorst M; Larsson LI;
    Br J Ophthalmol; 2004 Feb; 88(2):199-203. PubMed ID: 14736774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.